Recordati Licenses Exclusive Commercialization Rights of Juxtapid (lomitapide) from Aegerion Pharmaceuticals 

Shots:

• Aegerion (subsidiary of Novelion Therapeutics) to receive $25M upfront, $5M milestones, and royalties on sales of a product. Recordati to get exclusive commercialization rights for Aegerion’s Juxtapid in Japan
• The focus of the agreement is to develop & commercialize Juxtapid and to strengthen Recordati’s portfolio of rare diseases products in Japan
• Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor has received approval from Japan’s MHLW for homozygous familial hypercholesterolemia (HoFH), with sales of $10.8M in 2018, in Japan

Click here to read full press release/ article | Ref: Globe Newswire | Image: Amazon